Search results: (10000)
News Stable Position of Micronized Diosmin in the Treatment of Chronic Venous Insufficiency and Hemorrhoids
Diosmin is a flavonoid used in Europe as a venotonic and vasoprotective agent for over 40 years. Significant progress has been made in medicine during this time, yet the role of diosmin in the treatment of venous insufficiency and hemorrhoidal disease remains important. Diosmin itself has also evolved, being micronized for better biological availability and showing significant effects on the vascular system according to research.
News Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children – Results of the TERIKIDS Study
Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.
News Results of a 10-year follow-up on the safety and efficacy of etanercept treatment in patients with juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is defined as persistent arthritis of unknown etiology lasting > 6 weeks with the first onset before the age of 16. In the treatment of JIA, non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and conventional disease-modifying antirheumatic drugs (DMARDs) are typically utilized. In case of inadequate response, targeted biological therapy can also be used. An effective and well-tolerated drug for the treatment of polyarticular JIA is the tumor necrosis factor alpha (TNF-α) inhibitor etanercept. The results of its use in various forms of JIA were examined in the CLIPPER and CLIPPER2 studies.
News KDIGO: The Choice of Dialysis Modality Must Consider Patient Individuality
The moment of initiating dialysis, as well as the period immediately before and after it, is crucial for good treatment outcomes. But what exactly can be considered a good outcome, and do the perspectives of doctors and patients align on this issue? Leading nephrologists worldwide discussed this at the KDIGO conference, which was specifically focused on controversies in dialysis treatment.
News Use of Specific Inhibition of Anticoagulant Therapy During Heart Transplantation
A recent report from real clinical practice summarizes the experiences of physicians with dabigatran therapy and the reversal of its anticoagulant effect using idarucizumab in 10 patients before heart transplantation.
News Non-Invasive Diagnosis of Cardiac Amyloidosis
Cardiac amyloidosis has always been considered a rare pathology. However, thanks to advancements in imaging methods and laboratory tests, it is now evident that it might be responsible for a larger amount of cardiac diseases than previously thought. Which non-invasive diagnostic methods are useful in identifying cardiac amyloidosis?
News Are there mutual interactions between candesartan and amlodipine in the combination therapy of hypertension?
Monotherapy is often insufficient in the treatment of hypertension; however, combining antihypertensives with different mechanisms of action can be complicated by their mutual interactions. Therefore, a study by South Korean authors examined the pharmacokinetic interactions between candesartan and amlodipine, substances that are commonly used together in combined treatment.
News Progress on Lorlatinib – What's Next?
Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell lung cancer (NSCLC) with ALK gene rearrangement. Clinical research is now focusing on the question of how to proceed with patients who experience disease progression during lorlatinib treatment in later lines of therapy. It seems that one of the options might actually be to do nothing – to continue with lorlatinib.
News Cost-Effectiveness of Eletriptan in Acute Migraine Treatment
Even in a market dominated by generics, eletriptan 40 mg is among the most clinically effective and cost-efficient triptans for the acute treatment of migraine attacks. This was demonstrated by a systematic literature review focused on the pharmacoeconomic evaluation of this therapy, published by American authors in 2015. Its high cost-effectiveness may be due to its strong efficacy with a reduced need for additional treatment.
News Position of Generic Drugs in Oncology: What Are Their Main Advantages?
Generics – as is well known – are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has expired. They are applied in various medical fields, including oncology. The main goal of producing generics is to improve the accessibility of treatment for a wide range of patients while maintaining the safety and effectiveness of the therapy.
News Infographic and Commentary from Practice: Reasons and Pathways for Patients to Biological Treatment of Asthma
For asthma patients with the most severe forms of the disease to access targeted biological treatment, they must undergo examination at one of the specialized centers for severe asthma. To facilitate this pathway, a recommended procedure has been issued, from which we present a pragmatic extract for practice in the form of a clear infographic.
News Final Analysis of the STASEY Study: How Did Emicizumab Perform in Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?
The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a range of interesting topics. In its poster section, data from the multicenter single-arm open-label phase III clinical trial STASEY, which evaluated the safety and tolerance of emicizumab prophylaxis in patients with hemophilia A and an inhibitor of coagulation factor VIII (FVIII), were presented. Víctor Jiménez-Yuste from La Paz University Hospital in Madrid presented the study results on behalf of the international team of authors.
News Current NCCN Recommendations for Classification and Risk Symptoms in SLL/CLL
The new recommendations from the National Comprehensive Cancer Network (NCCN) regarding chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) from August 2022 also include a brief summary of the most common symptoms and methods for classifying the disease based on its extent at diagnosis or in case of progression.
News Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment – Case Study
In patients with immune thrombocytopenia (ITP), effectively stopping and controlling bleeding can be complicated in some cases. This includes scenarios such as open wounds. One way to stabilize platelet count can be through administering a thrombopoietin receptor agonist (TPO-RA). The following case study presents a successful treatment of newly diagnosed ITP.
News Quality of Life of Hemophiliacs and Ways to Improve It
Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.
News Morning Myopic Shift and Glare in Patients with Advanced Fuchs Endothelial Corneal Dystrophy
A newly published study by a German team analyzes the morning and afternoon differences in various parameters in patients with Fuchs endothelial corneal dystrophy to determine which of them contribute to subjective visual difficulties in the morning.
News How to Maintain Hygiene for Incontinent Patients Without Using Water?
Urinary incontinence brings numerous health risks. Due to frequent continuous contact of aggressive urine with the skin, a significant number of patients develop skin complications such as eczema, rashes, or even pressure sores. Maximum care should therefore be devoted to the hygiene of intimate areas in all incontinent patients.
News Position of Levodropropizine in Cough Therapy
An international group of specialists focused in 2016–2017 on a detailed evaluation of current options for cough therapy. The authors based their analysis on individually prepared reviews using Medline and Embase databases, and they presented their work's results last year in the journal Pulmonary Pharmacology & Therapeutics.
News Webinar SGLT2i in ESC HF Guidelines vs. Real Practice
Dear Doctor,
Boehringer Ingelheim, in collaboration with the 2nd Department of Internal Medicine - Department of Cardiology and Angiology,
General University Hospital and 1st Faculty of Medicine, Charles University, cordially invites you to an online discussion to be held on Tuesday, November 23, 2021, from 5:00 PM to 6:30 PM.
More information can be found in the attached invitation below.
News Erlotinib in Conditions of Routine Clinical Practice
The patient population in clinical trials is always somewhat selected. Only a well-conducted analysis of real-world clinical practice data can provide a clearer picture of the efficacy and safety of a drug. Therefore, we are currently witnessing a significant development in this type of clinical research, for example, in the form of nationwide cohort studies. How did erlotinib perform in one of them for the treatment of non-small cell lung cancer?
News Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the KRASG12C gene mutation, if there has been progression after ≥ 1 prior line of systemic therapy. The 2-year analysis of data from the CodeBreaK 100 study published in April 2023 demonstrated the long-term benefit of sotorasib for this patient population in terms of progression-free survival (PFS) and overall survival (OS), regardless of programmed death-ligand 1 (PD-L1) receptor expression, including patients with a poor prognosis. In the Czech Republic, sotorasib has been reimbursed by public health insurance for this indication since September 2023.
News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?
In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.
News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab
At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.
News FOLFOXIRI and Panitumumab in mCRC Treatment – Improvement in Treatment Response and Metastasis Resectability
For patients with metastatic colorectal cancer (mCRC) who are able to undergo intensive treatment, the FOLFOX (5-fluorouracil/leucovorin, oxaliplatin) or FOLFIRI (5-fluorouracil/leucovorin, irinotecan) regimens combined with monoclonal antibodies represent the standard first-line treatment. The FOLFOXIRI regimen, which is another option, was developed to further enhance the efficacy of chemotherapy. The German oncologists' VOLFI study investigated the effectiveness of combining targeted therapy and triplet chemotherapy compared to chemotherapy alone in previously untreated patients with mCRC without RAS oncogene mutation.